Mustang Bio (MBIO) Projected to Release Quarterly Earnings on Wednesday

Posted by Francis Steltz on Nov 11th, 2026

Mustang Bio (NASDAQ:MBIO – Get Free Report) is anticipated to announce its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to post earnings of ($140.00) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.

Mustang Bio (NASDAQ:MBIO – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($140.00) by $139.86.

Mustang Bio Stock Performance

MBIO stock opened at $0.45 on Wednesday. Mustang Bio has a one year low of $0.35 and a one year high of $1.43. The company’s fifty day moving average price is $0.45 and its 200-day moving average price is $0.67. The company has a market capitalization of $3.41 million, a PE ratio of -1.00 and a beta of 2.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

View Our Latest Stock Analysis on MBIO

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including cancer and rare genetic disorders. The company’s work centers on engineered immune-cell therapies designed to recognize and attack cancer cells, as well as gene therapies intended to address underlying disease causes. Mustang’s development programs have included CAR T-cell therapies for hematologic malignancies and solid tumors. Its pipeline has featured MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell cancers, and programs targeting glioblastoma and other difficult-to-treat cancers.